Navigation Links
BioMS Medical to present at BIO CEO & Investor Conference

Toronto Stock Exchange Symbol: MS

EDMONTON, Feb. 8 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BIO CEO & Investor Conference 2008 in New York.

WHEN: Tuesday February 12th at 11:45 am (Eastern Time)

WHERE: Waldorf Astoria Hotel, New York

About BIO CEO & Investor Conference


The objective of the conference is to bring together institutional investors, industry analysts, and senior biotechnology executives in a neutral and collaborative forum to examine investment opportunities and issues affecting the industry. For more information visit:

About BioMS Medical Corp.


BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such f

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
2. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
3. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
4. BioMS Medical announces third quarter 2007 results
5. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at BioContact 2007
8. BioMS Medical announces its intention to renew a normal course issuer bid
9. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
10. Linc Facility Services Acquires Morse Medical
11. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
(Date:10/8/2015)... PORTLAND, Oregon , October 8, 2015 /PRNewswire/ ... . --> Global Biologics and Biosimilars ... added a report "Global Biologics and Biosimilars Industry ... Growth, Analysis and Forecast" is a professional and ... Biosimilars industry . ) , ...
(Date:10/8/2015)... 8, 2015  Today the Wyss Institute for Biologically ... its start-up company Opsonix Inc. The announcement ... Office of Technology Development (OTD) and Opsonix Inc. ... for clinical use. --> ... million people every year in the U.S. — more ...
(Date:10/7/2015)... 8, 2015 ... accounts for largest bioinformatics market share due ... discovery and development process says this research ... . --> ... of applications, the bioinformatics market is segmented ...
(Date:10/7/2015)... Oct. 7, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of targeted antiviral ... offering of 5,000,000 shares of its common stock and ... Company,s common stock at a fixed combined price to ... and warrants will be issued separately.  The warrants will ...
Breaking Biology Technology:
... ... Finance Organizations , ... Redwood Shores, California (PRWEB) February 24, 2010 -- Model N , Inc., the ... Contract Authoring solution, which extends the Model N Revenue Management Suite by allowing business ...
... ... ... ... ...
... have discovered that, under the right conditions, newly ... tiny spaces between the geometric clusters of atoms ... This finding, detailed recently in the journal ... becoming more ubiquitous in the fabrication of microdevices ...
Cached Biology Technology:
(Date:9/9/2015)... 2015  NuData Security announced today that it ... the company,s commitment to protecting organizations and individuals ... NuData Security,s online fraud detection solution, NuDetect, has ... The product combines continual analysis and behavioral biometrics ... from fraudulent behavior, allowing the company to detect ...
(Date:9/2/2015)... , Sept. 2, 2015 About hand geometry ... enterprises, banks, government organizations, telecommunication and hospitals as well ... identity badges, and numeric keypads are used to prevent ... of palm and fingers of an individual, width of ... scanners with infrared light and reflectors can be used ...
(Date:9/1/2015)... , Sept. 1, 2015  Automation and pre-processing ... airport passenger screening. This is the first step ... process will become unintrusive. An assortment of portal ... voluntary background investigations will transform the passenger screening ... Sullivan, Global Airport Passenger Screening Market ...
Breaking Biology News(10 mins):
... certain fish are capable of glowing red. Research published ... of fish fluorescing vivid red light. Due to ... which look red under normal conditions appear grey or ... the belief among marine biologists that red colours are ...
... , Researchers at the U.S. National Institutes of Health ... simple antiviral drug developed decades ago suppresses HIV in patients ... in the Sept. 11 issue of the journal Cell ... led by Dr. Leonid Margolis made the initial discovery, while ...
... press release is available in German . ... UFZ German scientist found that the worldwide economic ... bees mainly, was 153 billion in 2005 for the ... to 9.5% of the total value of the world ...
Cached Biology News:
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... Performance, 5 ml. The same high ... Streptavidin columns for fast, reliable purification ... Tricorn 5/50 GL, XK 16/20, or ... are required.Extremely useful for exploiting either ...
Biology Products: